Parkinson's disease

R&D

The importance of time: Grifols seeks biomarkers for early d...

Through a pioneering initiative called Chronos-PD, Grifols is partnering with the Michael J.

News

plasma test tubes being placed by a gloved hand in a lab

Grifols gets $21m award for Parkinson's biomarker hunt

Grifols has been awarded a $21m grant from the Michael J Fox Foundation to find plasma biomarkers to predict Parkinson's years before symptoms start.

News

Bayer gains ground in two-fronted Parkinson's offensive

Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.

News

Roche's Parkinson's hope fails second clinical trial

Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals.

News

AbbVie gets continuous Parkinson's drug over the line in US

AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator turned it down with a request for more data.

News

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial.

The importance of time: Grifols seeks biomarkers for early d...

Grifols gets $21m award for Parkinson's biomarker hunt

Bayer gains ground in two-fronted Parkinson's offensive

Roche's Parkinson's hope fails second clinical trial

AbbVie gets continuous Parkinson's drug over the line in US

MeiraGTx plans to take Parkinson's gene therapy into phase 3

Allogeneic cell therapy isn’t dead, with Brian Culley

How to meet your physicians where they are online

Parkinson's disease

Editor's Picks